TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

3 Cutting-Edge Biotech Stocks That Can Double in Value
MERGERS AND ACQUISITIONS

Why 2018 will be better for biotech deals than 2017

PRESS RELEASES

Ziopharm Oncology Announces Election Of James Huang As Chairman Of The Board Of Directors

PRESS RELEASES

Ziopharm Oncology Announces Clearance Of Taiwan's First IND Of Non-viral CAR-T For The Treatment Of Relapsed CD19 Leukemias And Lymphomas

PRESS RELEASES

WaterMill Asset Management Issues Statement Regarding Consent Solicitation At Ziopharm Oncology

PRESS RELEASES

Ziopharm Comments On Consent Solicitation Results

PRESS RELEASES

Ziopharm Oncology Announces Chief Financial Officer To Step Down

PRESS RELEASES

WaterMill Asset Management Addresses Ziopharm Oncology's Latest Distortion And Recent Threat

PRESS RELEASES

Ziopharm Comments On Delay Of WaterMill's Stated Consent Deadline

PRESS RELEASES

Egan-Jones Recommends Against Electing Dissident's Full Slate Of Nominees To Ziopharm Board

PRESS RELEASES

WaterMill Asset Management Reinforces The Need For Meaningful And Urgent Change At Ziopharm Oncology

PRESS RELEASES

Glass Lewis Recommends Ziopharm Shareholders Vote On The WHITE Consent Card For All Of WaterMill's Director Candidates And Proposals

PRESS RELEASES

WaterMill Asset Management Refutes Ziopharm Oncology's Desperate, Low-Road Smear Campaign

PRESS RELEASES

Ziopharm Comments On Institutional Shareholder Services' Recommendation To Reject WaterMill's Attempt To Remove Half Of Ziopharm's Board Of Directors

PRESS RELEASES

 ISS Recommends Ziopharm Shareholders Vote For Change On WaterMill Asset Management's WHITE Consent Card

PRESS RELEASES

WaterMill Asset Management Sets The Record Straight Following Ziopharm's Apparent Attempt To Mislead Shareholders And Rewrite History

PRESS RELEASES

Ziopharm Releases Investor Presentation Highlighting Execution Of Strategy And Substantial Board Refreshment To Enhance Shareholder Value

PRESS RELEASES

WaterMill Asset Management Releases Presentation Detailing The Case For Urgent Change Atop Ziopharm Oncology

PRESS RELEASES

Ziopharm Oncology Presents Encouraging Clinical Data For Controlled IL-12 For The Treatment Of Glioblastoma And DIPG At The 2020 Society For Neuro-Oncology Annual Meeting

PRESS RELEASES

White Rock Capital Supports WaterMill's Case For Change At Ziopharm Oncology

PRESS RELEASES

Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., As Chief Medical Officer

PRESS RELEASES

Ziopharm Oncology Appoints Mary Thistle To Board Of Directors

PRESS RELEASES

WaterMill Asset Management Releases Candid Q&As With Each Of Its Director Candidates For Election To Ziopharm Oncology's Board

PRESS RELEASES

Ziopharm Oncology To Report Third Quarter 2020 Financial Results And Host A Conference Call And Webcast On November 5, 2020

PRESS RELEASES

Ziopharm Oncology Announces Receipt Of Shareholders' Intent To Solicit Written Consents

PRESS RELEASES

Ziopharm Oncology To Participate In Jefferies Cell Therapy Virtual Summit On October 5, 2020